FORM	4
------	---

-
Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Response	ses)										
1. Name and Address Fust Matthew K	2. Issuer Name an Atara Biotherape			0.2	ol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) C/O ATARA BIOT GATEWAY BOUT	S, INC., 701	3. Date of Earliest Transaction (Month/Day/Year) 01/16/2015							ther (specify below	ow)	
SOUTH SAN FRA		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	-	Code (A) or Disposed of (D)			isposed o	of (D)		Ownership Form:	Beneficial
			(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4. 5. Number		6. Date Exercisable and		7. Title and		8. Price of	9. Number of	10.	11. Nature		
Derivative	Conversion	Date	Execution Date, if	Transaction of		Expiration Date		Amount of		Derivative	Derivative	Ownership	of Indirect		
		(Month/Day/Year)		Code		Derivativ	ve	(Month/Day	/Year)	Underlying Security				Beneficial	
· · · ·	Price of		(Month/Day/Year)	(Instr. 8)		Securities		· · · · · · · · · · · · · · · · · · ·		· /	2	Derivative	1		
	Derivative					-		(Instr. 3 and 4)				(Instr. 4)			
	Security						A) or				0	Direct (D)			
						Disposed	1 01						1	or Indirect	
						(D) (Instr. 3,	4			Transaction(s) (Instr. 4)	(1) (Instr. 4)				
						and 5)	ч,				(1130.4)	(1130.4)			
											Amount	-			
											or				
									Expiration		Number				
								Exercisable	Date		of				
				Code	V	(A)	(D)				Shares				
Non-															
Qualified															
Stock										Common					
Option	\$ 25.15	01/16/2015		Α		12,500		<u>(1)</u>	01/16/2022	Common Stock	12,500	\$ 0	12,500	D	
										SIOCK					
(Right to															
Buy)															

Reporting Owners

Duranting Orman Name (Addams	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Fust Matthew K C/O ATARA BIOTHERAPEUTICS, INC. 701 GATEWAY BOULEVARD, SUITE 200 SOUTH SAN FRANCISCO, CA 94080	Х							

Signatures

/s/ Tina Gullotta, Attorney-in-Fact for Matthew K. Fust	01/21/2015
	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option will vest 100% on January 1, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.